| Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study CJ Langer, SM Gadgeel, H Borghaei, VA Papadimitrakopoulou, A Patnaik, ... The lancet oncology 17 (11), 1497-1508, 2016 | 1485 | 2016 |
| 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without Pembrolizumab as first-line therapy for advanced nonsquamous non–small cell lung … H Borghaei, CJ Langer, S Gadgeel, VA Papadimitrakopoulou, A Patnaik, ... Journal of Thoracic Oncology 14 (1), 124-129, 2019 | 214 | 2019 |
| Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial GJ Riely, JW Neal, DR Camidge, AI Spira, Z Piotrowska, DB Costa, ... Cancer discovery 11 (7), 1688-1699, 2021 | 198 | 2021 |
| Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD (L)-1 … JD Schoenfeld, A Giobbie-Hurder, S Ranasinghe, KZ Kao, A Lako, J Tsuji, ... The Lancet Oncology 23 (2), 279-291, 2022 | 147 | 2022 |
| KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the … CJ Langer, SM Gadgeel, H Borghaei, VA Papadimitrakopoulou, A Patnaik, ... Lancet Oncol 17 (11), 1497-1508, 2016 | 135 | 2016 |
| A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research … GA Durm, SK Jabbour, SK Althouse, Z Liu, AA Sadiq, RT Zon, SI Jalal, ... Cancer 126 (19), 4353-4361, 2020 | 131 | 2020 |
| Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC MM Awad, SM Gadgeel, H Borghaei, A Patnaik, JCH Yang, SF Powell, ... Journal of Thoracic Oncology 16 (1), 162-168, 2021 | 127 | 2021 |
| Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC) RD Hall, TM Le, DE Haggstrom, RD Gentzler Translational lung cancer research 4 (5), 515, 2015 | 125 | 2015 |
| A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes YK Chae, L Chiec, N Mohindra, R Gentzler, J Patel, F Giles Cancer Immunology, Immunotherapy 66, 25-32, 2017 | 124 | 2017 |
| Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non–small cell lung cancer to the brain: a matched cohort study MJ Shepard, Z Xu, J Donahue, TJE Muttikkal, D Cordeiro, L Hansen, ... Journal of neurosurgery 133 (3), 685-692, 2019 | 99 | 2019 |
| Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 … A Passaro, J Wang, Y Wang, SH Lee, B Melosky, JY Shih, K Azuma, ... Annals of Oncology 35 (1), 77-90, 2024 | 75 | 2024 |
| Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors R Gentzler, R Hall, PR Kunk, E Gaughan, P Dillon, CL Slingluff Jr, ... Immunotherapy 8 (5), 583-600, 2016 | 74 | 2016 |
| Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network … GA Durm, SK Althouse, AA Sadiq, SI Jalal, S Jabbour, R Zon, ... Journal of Clinical Oncology 36 (15_suppl), 8500-8500, 2018 | 73 | 2018 |
| A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer AM Monjazeb, A Giobbie-Hurder, A Lako, EM Thrash, RC Brennick, ... Clinical Cancer Research 27 (9), 2470-2480, 2021 | 71 | 2021 |
| OA04. 05 KEYNOTE-021: TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for nonsquamous NSCLC C Langer, S Gadgeel, H Borghaei, A Patnaik, S Powell, R Gentzler, ... Journal of Thoracic Oncology 14 (10), S216, 2019 | 62 | 2019 |
| F‐18 FDG‐PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem‐cell transplantation for relapsed and refractory H odgkin lymphoma RD Gentzler, AM Evens, AW Rademaker, BB Weitner, BB Mittal, ... British journal of haematology 165 (6), 793-800, 2014 | 52 | 2014 |
| Bilateral anterior uveitis associated with nivolumab therapy J Karlin, R Gentzler, J Golen Ocular Immunology and Inflammation 26 (2), 283-285, 2018 | 46 | 2018 |
| Updated results from KEYNOTE-021 cohort G: a randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for … H Borghaei, CJ Langer, S Gadgeel, VA Papadimitrakopoulou, A Patnaik, ... Annals of Oncology 28, v636-v637, 2017 | 46 | 2017 |
| Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature J Gao, RD Gentzler, AE Timms, MS Horwitz, O Frankfurt, JK Altman, ... Journal of hematology & oncology 7, 1-7, 2014 | 44 | 2014 |
| An overview of the mTOR pathway as a target in cancer therapy RD Gentzler, JK Altman, LC Platanias Expert Opinion on Therapeutic Targets 16 (5), 481-489, 2012 | 43 | 2012 |
